The RealReal Announces Inducement Grants under Nasdaq 4-03-2023, 05:03

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research 20-02-2025, 19:00